Currently, Dr. Stein serves as the chief medical officer and executive vice president at the biopharmaceutical company Incyte. Prior to this role, Dr. Stein held leadership roles at Novartis Pharmaceuticals Corp., according to an Oct. 19 Theseus news release.
“We are delighted to welcome Dr. Stein to the Theseus Board as we advance development of our THE-630 and THE-349 programs, while also expanding our early-stage pipeline,” Tim Clackson, PhD, president and CEO of Theseus, said in the news release. “Dr. Stein’s depth and breadth of oncology expertise, and extensive track record of bringing effective medicines through development and to patients, will be invaluable as we continue to build Theseus as a leading precision oncology company.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
